Potassium Ion

Potassium Ion

SCHEMBL1334434

C=C(C)COCCCS(=O)(=O)[O-].[K+]

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 2/20 0.36
GMNN O75496 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
THPO P40225 1/20 0.33
HBB P68871 1/20 0.33
PMP22 Q01453 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CES2 O00748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11769924 0.96 GMNN (0.38) BBOX1GMNNALDH1A1LMNATP53
Lithium Ion SCHEMBL1303199 0.85 KDM4E (0.33) BBOX1
SCHEMBL1303309 0.85 KDM4E (0.38) BBOX1GMNNALDH1A1LMNATP53
SCHEMBL973803 0.81 APP (0.37) LMNACES2
SCHEMBL4056939 0.80 BBOX1 (0.53) BBOX1LMNA
SCHEMBL6259281 0.79 CES2 (0.33) CES2
Potassium Ion SCHEMBL31075019 0.77 GMNN (0.46) BBOX1GMNNALDH1A1LMNATP53
SCHEMBL7770974 0.76 CES2 (0.37) CES2
SCHEMBL7256155 0.75 CES2 (0.39) TSHRCES2
SCHEMBL871697 0.75 CES2 (0.44) TSHRCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8753686-B2 Surface-treating agents, surface-treated powders, and cosmetics comprising the same SHISEIDO CO., LTD. (JP) 2014-06-17 US disclosed
US-20110280946-A1 Surface-Treating Agents, Surface-Treated Powders, And Cosmetics Comprising The Same SHISEIDO CO., LTD. (JP) 2011-11-17 US disclosed
EP-2112179-B1 Surface-treated powders, and cosmetics comprising the same SHISEIDO CO LTD (JP) 2011-04-27 EP disclosed
EP-1803750-B1 USE OF A POLYMER FOR SURFACE-TREATING A POWDER SHISEIDO CO LTD (JP) 2009-12-09 EP disclosed
EP-2112179-A1 Surface-treated powders, and cosmetics comprising the same Shiseido Co., Ltd. (JP) 2009-10-28 EP disclosed
US-20080081029-A1 acrylic homopolymers or copolymers, that can provide excellent hydrophobicity to powders or cosmetics, and can improve its rinsability SHISEIDO CO., LTD. (JP) 2008-04-03 US disclosed
EP-1803750-A1 SURFACE-TREATING AGENT, SURFACE-TREATED POWDER, AND COSMETIC PREPARATION CONTAINING SAME Shiseido Company, Limited (JP) 2007-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081029-A1 acrylic homopolymers or copolymers, that can provide excellent hydrophobicity to powders or cosmetics, and can improve its rinsability CHRM1, H1-0, H1-2 BBOX1 2452/4885GMNN 2440/4885ALDH1A1 142/4885
US-20110280946-A1 Surface-Treating Agents, Surface-Treated Powders, And Cosmetics Comprising The Same CHRM1, H1-0, H1-2 BBOX1 2055/4885GMNN 2944/4885ALDH1A1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.